GV20 Therapeutics

📍 Cambridge, United States🗓 Founded 2016👥 24 employees💰 Last funded May 2017
Biotechnology Research🌐 gv20tx.com
Website LinkedIn
GV20 Therapeutics (https://gv20tx.com) was incorporated in 2016 with sites in Cambridge, USA, and Shanghai, China. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20s proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in GV20 Therapeutics?
GV20 Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did GV20 Therapeutics last raise funding?
The most recent investment in GV20 Therapeutics recorded on gritt.io was in May 2017.
When was GV20 Therapeutics founded?
GV20 Therapeutics was founded in 2016.
What industry is GV20 Therapeutics in?
GV20 Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GV20 Therapeutics based?
GV20 Therapeutics is headquartered in Cambridge, United States.